Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers

Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles

(2015) F. Tiberg et al.   JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update

(2013) Laurence Katznelson et al.   Endocrine Practice

Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors

(2013) Pamela L. Kunz et al.   PANCREAS

Systemic Therapeutic Options for Carcinoid

(2013) Marianne Pavel et al.   SEMINARS IN ONCOLOGY

Phase Behavior, Functions, and Medical Applications of Soy Phosphatidylcholine and Diglyceride Lipid Compositions

(2012) Fredrik Tiberg et al.   CHEMISTRY LETTERS

The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options

(2011) K.E. Öberg   CLINICAL ONCOLOGY

Octreotide Long-Acting Release (LAR)

(2010) Lily P.H. Yang et al.   DRUGS

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

(2009) Lowell Anthony et al.   CURRENT MEDICAL RESEARCH AND OPINION